Literature DB >> 1511427

Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines.

K P Hoyes1, R C Hider, J B Porter.   

Abstract

The effect of bidentate 3-hydroxypyridin-4-one (HPO) iron chelators on cell cycle arrest with subsequent cycle synchronization has been compared with that of the hexadentate desferrioxamine (DFO) in K562 and Daudi cells. The relationships between chelator concentration and inhibition of growth, DNA synthesis and ribonucleotide reductase, and phase of cell cycle arrest have also been explored. HPOs and DFO arrest the cell cycle in a dose-dependent manner causing a blockade at the G1-S border after 24 h at concentrations above 30 microM iron-binding equivalents. This is associated with reduced ribonucleotide reductase activity and concomitant cessation of DNA synthesis and growth. When the chelator is subsequently removed, HPO-treated cells synchronously cascade into S phase, unlike DFO-treated cells which resume cycling in a nonsynchronous manner. Chelator concentrations of approximately 25 microM and 3 microM iron-binding equivalents inhibited growth, DNA synthesis, and ribonucleotide reductase activity by 50% in K562 and Daudi cells, respectively. Concentrations less than 10 microM iron-binding equivalents inhibited K562 cell growth without an effect on DNA synthesis but with accumulation of cells in G2 and M phases. These results suggest that HPOs have advantages over DFO as cell cycle synchronization agents and may be useful adjuncts in cell cycle-specific treatment regimens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1511427

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Cellular adaptation to down-regulated iron transport into lymphoid leukaemic cells: effects on the expression of the gene for ribonucleotide reductase.

Authors:  C R Chitambar; J P Wereley; T Heiman; W E Antholine; W J O'brien
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

2.  Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells.

Authors:  Kyu Kwang Kim; Thilo S Lange; Rakesh K Singh; Laurent Brard
Journal:  BMC Cancer       Date:  2010-02-25       Impact factor: 4.430

3.  Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation.

Authors:  Jolyn Turner; Constantinos Koumenis; Timothy E Kute; Roy P Planalp; Martin W Brechbiel; Dillon Beardsley; Brooke Cody; Kevin D Brown; Frank M Torti; Suzy V Torti
Journal:  Blood       Date:  2005-07-12       Impact factor: 22.113

Review 4.  Role of metal dyshomeostasis in Alzheimer's disease.

Authors:  David J Bonda; Hyoung-gon Lee; Jeffrey A Blair; Xiongwei Zhu; George Perry; Mark A Smith
Journal:  Metallomics       Date:  2011-02-07       Impact factor: 4.526

Review 5.  Nanoparticle delivery of transition-metal chelators to the brain: Oxidative stress will never see it coming!

Authors:  David J Bonda; Gang Liu; Ping Men; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-02       Impact factor: 4.388

6.  Iron chelation-induced senescence-like growth arrest in hepatocyte cell lines: association of transforming growth factor beta1 (TGF-beta1)-mediated p27Kip1 expression.

Authors:  Gyesoon Yoon; Hyun-Jung Kim; Young-Sil Yoon; Hyeseong Cho; In K Lim; Jae-Ho Lee
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

7.  Mimosine, a novel inhibitor of DNA replication, binds to a 50 kDa protein in Chinese hamster cells.

Authors:  P J Mosca; H B Lin; J L Hamlin
Journal:  Nucleic Acids Res       Date:  1995-01-25       Impact factor: 16.971

8.  Synthesis and biological evaluation of bidentate 3-hydroxypyridin-4-ones iron chelating agents.

Authors:  L Saghaie; H Sadeghi-Aliabadi; M Kafiri
Journal:  Res Pharm Sci       Date:  2011-07

Review 9.  A risk-benefit assessment of iron-chelation therapy.

Authors:  J B Porter
Journal:  Drug Saf       Date:  1997-12       Impact factor: 5.228

10.  Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator.

Authors:  Evangelia Vlachodimitropoulou; Yu-Lin Chen; Maciej Garbowski; Pimpisid Koonyosying; Bethan Psaila; Martha Sola-Visner; Nichola Cooper; Robert Hider; John Porter
Journal:  Blood       Date:  2017-09-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.